The second award ceremony of top 50 biotechnological innovation enterprises in GBA and GBA biotechnology development summit, hosted by China Innovation Industry Research Institute and KPMG China, were held in Guangzhou on October 16, 2019. After more than five months of selection and evaluation by the authority, the list was officially released. Hybribio was elected as the “Top 50 Leading Biotechnological innovation enterprises in GBA in 2019”.

The award ceremony

Award of leading enterprise

The selection of top 50 biotechnological innovation enterprises was initiated on the background of the 13th five-year national plan and the ‘healthy China’ construction. The consulting team, consisted of government agencies, third-party research authorities, professional investors, medical institutions, etc., evaluates the enterprise using innovation as the main index and referring to different developing stage of the enterprises. Meanwhile, technology, market and investigation are taken into account. It aims to cultivate an innovative ecology where manufacture, education and research are integrated, to develop unicorn enterprises in the biotechnological industry, and to promote in-depth development of the industry.

Hybribio, as a high-tech enterprise, keep in step with the national health industry to promote in-depth cooperation of the medical industry in GBA and push to the establishing the “GBA precision medical industry alliance” which will promote the coordinated development and sharing of Guangdong, HongKong and Macao. Through continuous investigation, Hybribio established services, such as reproduction health care, prenatal and postnatal care, birth defect prevention and control, and tumor gene detection, on platforms such as diversion hybridization technology platform which Hybribio has independent intellectual property rights, internationally-universal fluorescence PCR, digital PCR, and high-throughput sequencing. Hybrio established a layout of diversified platforms for products and steadily promotes the sustainable development of the health industry.

Hybirbio has been listed twice for the ‘Top 50 Biotechnological Innovation enterprises’ in GBA, which is the approval of Hybribio’s advanced development in the nucleic acid detection field as well as the affirmation of Hybribio’s prospects from the government and the health industry. Taking this great opportunity, Hybribio will keep on playing its core advantages, basing on the domestic market and global perspectives. Hybribio will further improve its advanced medical diagnostic technology and contribute more to human health care, with innovation being the key.